Premium
Position statement: Nonanesthesiologist administration of propofol for GI endoscopy
Author(s) -
Vargo John J.,
Cohen Lawrence B.,
Rex Douglas K.,
Kwo Paul Y.
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23326
Subject(s) - position statement , propofol , medicine , endoscopy , administration (probate law) , position (finance) , statement (logic) , anesthesia , general surgery , political science , business , law , family medicine , finance
This statement on the use of nonanesthesiologist-administered propofol (NAAP) for GI endoscopy is issued jointly by The American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy. A 4-member committee, composed of a representative from each society, prepared the firstdraftofthis document, which was then reviewed and approved by the governing board of each organization. This document is designed to provide an evidence-based assessment of propofol mediated sedation by properly trainedgastroenterologists and other nonanesthesiologists. The safety, efficacy, cost-effectiveness, and training issues involved with nonanesthesiologist administration of propofol for GI endoscopy are reviewed, and a series of concluding statements and recommendations are provided Whenever possible, these summary conclusions aregraded based upon the strength ofthe supporting evidence (Table 1).